Active Pharmaceutical Ingredients Market Size To Worth Over US$ 284.3 Billion in Terms of Revenue by 2020 to 2027 | Industry Share, Trends, Growth, Demand | Finds CMI
Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Global Active Pharmaceutical Ingredients Market, by API (Branded/ Innovative and Generic), By Type of Synthesis (Synthetic and Biotech), by Application (Diabetes, Oncology, Cardiovascular, CNS, Analgesics, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 180.4 billion in 2020 and is estimated to exhibit a CAGR of 6.7% over the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.
Request Sample Copy of the Business Report: https://www.coherentmarketinsights.com/insight/request-sample/738
Increasing investments in research and development by manufacturers is expected to augment the market growth, over the forecast period.
Major pharmaceutical companies are focusing on expansion of their product line in high potency API (HPAPIs) and also focuses on investing in new HPAPI production facilities, for further outsourcing manufacturing of API’s to contract manufacturers. This in turn will increase the benefits from the latter’s competency and expertise, as captive manufacturing of HPAPI is expensive and requires stringent safety and handling specifications. This factors are expected to drive growth of the active pharmaceutical ingredients market over the forecast period.
Moreover, outsourcing of API manufacturing is rapidly increasing in economies such as India, China, and Eastern European countries, owing to the low cost of manufacturing in these economies in comparison to North America and Western Europe regions. For instance, in October 2017, Piramal Pharma Solutions (PPS), a contract development and manufacturing organization, invested US$ 55 million across its sites in Asia to expand its API manufacturing capabilities and capacities. Furthermore, in October 2018, Lonza, Switzerland-based biopharma CDMO, expanded its highly potent active pharmaceutical ingredient (HPAPI) capacity for supporting antibody-drug conjugate (ADC) payload manufacturing. It added two new manufacturing facilities at its Visp site for manufacturing of antibody-drug conjugate (ADC) payload.
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get an Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/738
Additionally, high potency active pharmaceutical ingredients are considered as a growth opportunity for pharmaceutical manufacturers and contract manufacturing organizations (CMOs) with much R&D focusing on specialized medicines, especially in the field of oncology. The increasing demand for antibody drug conjugates (ADC) is expected to fuel the active pharmaceutical ingredients market growth over the forecast period. For instance, according to the IMS Institute of Healthcare Informatics, 2016, 586 drugs were under development for oncology treatment, with over 70 new cancer treatments (for over 20 tumor types) that entered market during 2010-2015.
Key Takeaways of the Active Pharmaceutical Ingredients Market:
- The global active pharmaceutical ingredients market is expected to exhibit a CAGR of 6.7% over the forecast period, attributed to increasing demand for high potency APIs, rising demand for offering API manufacturing, and increasing prevalence of chronic diseases such as cancer
- Among type of synthesis, synthetic segment is expected to hold a dominant position in the active pharmaceutical ingredients market in 2018, attributed to innovations in the technique adopted by key players for synthesizing chemically-active pharmaceutical ingredients to enhance their potency and stability
- Among application, diabetes segment is expected to hold a dominant position in the active pharmaceutical ingredients market in 2018, attributed to increasing incidence of diabetes and rising number of regulatory approvals of various diabetic drugs. For instance, in June 2014, the European Medicines Agency authorized first biosimilar of insulin Glargine, Abasaglar from Eli Lilly and Company and Boehringer Ingelhim International GmBh, for treatment of diabetes mellitus. In 2016, this biosimilar received the FDA approval in the U.S.
- Key players operating in the global active pharmaceutical ingredients market include Teva Pharmaceutical Industries Ltd., Pfizer, Inc., BASF SE, Dr. Reddy’s Laboratories Ltd., Novartis AG, Mylan N.V., Sanofi S.A., and Lonza
Browse 32 Market Data Tables and 20 Figures spread through 178 Pages and in-depth TOC on “Active Pharmaceutical Ingredients Market”- Global Forecast to 2026, by API (Branded/ Innovative and Generic), By Type of Synthesis (Synthetic and Biotech), by Application (Diabetes, Oncology, Cardiovascular, CNS, Analgesics, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in the active pharmaceutical ingredients market press release, click the link below: https://www.coherentmarketinsights.com/press-release/active-pharmaceutical-ingredients-market-to-surpass-us-2749-billion-by-2026-1369
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Product Type
- Market Snippet, By Molecule Type
- Market Snippet, By Formulation
- Market Snippet, By Application
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Regulatory Scenario
- Market Trends
- API Patent Expiration
- Pipeline Analysis
- ANDA/DMF Intelligence
- Production Capability Analysis
- Vertically Integrated Businesses
- PEST Analysis
- Reimbursement Scenario (Medicare Part D Spending)
- Market Dynamics
- Global Active Pharmaceutical Ingredients Market – Impact of Coronavirus (COVID-19) Pandemic
- Economic Impact
- Manufacturing
- Regulations
- Government Measures to Combat COVID-19
- Global Active Pharmaceutical Ingredients Market, By Product Type, 2016 – 2027, (US$ Bn)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- High Potent APIs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
- Low Potent APIs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
- Introduction
- Global Active Pharmaceutical Ingredients Market, By Molecule Type, 2016 – 2027, (US$ Bn)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Small Molecules
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
- Large Molecules
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
- Introduction
- Global Active Pharmaceutical Ingredients Market, By Formulation, 2016 – 2027, (US$ Bn)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
- Topical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
- Injectables
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
- Drops
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
- Introduction
- Global Active Pharmaceutical Ingredients Market, By Applic, 2016 – 2027, (US$ Bn)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
- Oncology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
- Cardiovascular
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
- CNS
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
- Analgesics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
- Dermatology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
- Respiratory
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
- Ophthalmic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
- Introduction
- Global Active Pharmaceutical Ingredients Market, By Region, 2016 – 2027, (US$ Bn)
- Introduction
- Market Share Analysis, By Region, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, For Regions, 2017–2027
- North America
- Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Bn)
- Market Size and Forecast, By Molecule Type, 2016 – 2027, (US$ Bn)
- Market Size and Forecast, By Formulation, 2016 – 2027, (US$ Bn)
- Market Size and Forecast, By Application, 2016 – 2027, (US$ Bn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Bn)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Bn)
- Market Size and Forecast, By Molecule Type, 2016 – 2027, (US$ Bn)
- Market Size and Forecast, By Formulation, 2016 – 2027, (US$ Bn)
- Market Size and Forecast, By Application, 2016 – 2027, (US$ Bn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Bn)
- Market Size and Forecast, By Molecule Type, 2016 – 2027, (US$ Bn)
- Market Size and Forecast, By Formulation, 2016 – 2027, (US$ Bn)
- Market Size and Forecast, By Application, 2016 – 2027, (US$ Bn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Bn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Bn)
- Market Size and Forecast, By Molecule Type, 2016 – 2027, (US$ Bn)
- Market Size and Forecast, By Formulation, 2016 – 2027, (US$ Bn)
- Market Size and Forecast, By Application, 2016 – 2027, (US$ Bn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Bn)
- Market Size and Forecast, By Molecule Type, 2016 – 2027, (US$ Bn)
- Market Size and Forecast, By Formulation, 2016 – 2027, (US$ Bn)
- Market Size and Forecast, By Application, 2016 – 2027, (US$ Bn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Bn)
- Market Size and Forecast, By Molecule Type, 2016 – 2027, (US$ Bn)
- Market Size and Forecast, By Formulation, 2016 – 2027, (US$ Bn)
- Market Size and Forecast, By Application, 2016 – 2027, (US$ Bn)
- Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Bn)
- South Africa
- Central Africa
- North Africa
- Introduction
- Competitive Landscape
- Heat Map Analysis
- Company Profiles
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Pfizer, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Endo International plc
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Reddy’s Laboratories Ltd.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Novartis AG
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Mylan N.V.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Amneal Pharmaceuticals LLC
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Lonza Group
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Stada Arzneimittel AG
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Lupin Limited
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Fresenius Kabi
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Hikma Pharmaceuticals
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Aurobindo Pharma Limited
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Apotex, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Cipla Limited
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Taro Pharmaceutical Industries Ltd.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Biological E. Limited
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- CordenPharma International
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Evonik Industries AG
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Glenmark Pharma
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Krka Pharmaceuticals
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Teva Pharmaceutical Industries Ltd.
- Section
- Research Methodology
- About us and Sales Contact
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
Editor Details
-
Company:
- CDN Newswire
